Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

D.C., for his stem cell collection — the first major step of the revolutionary sickle cell gene therapy process. “But that also comes with the skepticism of: Will it really work?” It’s the same ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Sickle cell patient advocacy groups in the US are calling for greater education on the disease and increasing awareness of blood therapy.